Cancer death disproportionately burdens low- and middle-income countries (LMICs), which account for 70% of all cancer deaths worldwide.1-4 Limited capacity to provide necessary cancer therapy in LMICs is multifactorial and, beyond material resource constraints, is caused by a lack of provider training and infrastructure development.5 For instance, locally advanced cervical cancer, a leading cause of death in women in LMICs,6-8 is often curable with high-dose-rate (HDR) brachytherapy.9-12 HDR...
